Expertise in
11
conditions

Yasuhito Terui

Saitama, JP 
Expertise in
11
conditions
Saitama, JP 

Overview

Yasuhito Terui practices practicing medicine in Saitama, Japan.

Terui is highly rated in 11 conditions, according to our data. Their clinical expertise encompasses Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Peripheral T-Cell Lymphoma.

They are actively involved in clinical research, co-authoring 87 peer reviewed articles and participating in 1 clinical trial.

Locations

Saitama, Japan
Other Locations
Japan
Tokyo, Japan
Morohongo, 3500495, Japan
Iruma, Japan
Yankebetsu, Japan
Ariake, 1358550, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Japanese Participants With Relapsed/Refractory Multiple Myeloma
A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Japanese Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Bortezomib, Dexamethasone, Pomalidomide
Study Phase: Phase 1

87 Total Publications

Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Feasibility of Salvage Therapy With High-Dose Bendamustine and Rituximab Based on a Series of Two Cases From a Planned Phase II Trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Journal: Cureus
Published: January 29, 2026

Frequently Asked Questions about Yasuhito Terui

Is Yasuhito Terui a top-rated expert for Diffuse Large B-Cell Lymphoma (DLBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Yasuhito Terui is classified as an Distinguished expert for Diffuse Large B-Cell Lymphoma (DLBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yasuhito Terui participate in research or clinical trials?

Yes. Yasuhito Terui has published 87 articles and abstracts on conditions like Diffuse Large B-Cell Lymphoma (DLBCL). You can view a list of Yasuhito Terui's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Terui's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile